inhibitor Archives - Family Medicine News

Inflammation inhibitor delivered directly to kidneys reverses course of destructive nephritis

30.07.2018 Health Problems

Using a manmade version of a human antibody to directly deliver a drug that inhibits a powerful driver of inflammation, can reverse a disease course that often leads to kidney failure and dialysis, investigators report. They have additionally found that it’s the powerhouses of kidney cells, called mitochondria, that are particularly impacted by the acute or chronic inflammation called nephritis, […]

Checkpoint inhibitor shrinks advanced squamous cell skin cancer

05.06.2018 Health Problems

Clinical trials show that an immune checkpoint inhibitor shrinks the tumors of nearly half of patients with an incurable, advanced form of a common skin cancer, an international team led by a researcher at The University of Texas MD Anderson Cancer Center reports in the New England Journal of Medicine. “These results mark a potential paradigm shift in the treatment […]

Study of acute myeloid leukemia patients shows protein inhibitor drug safe and effective with durable remissions

03.06.2018 Health Problems

Ivosidenib, an experimental drug that inhibits a protein often mutated in several cancers has been shown to be safe, resulting in durable remissions, in a study of acute myeloid leukemia (AML) with relapsed or refractory disease. The multi-center Phase I trial, led by researchers at The University of Texas MD Anderson Cancer Center, was designed to determine ivosidenib’s safety and […]

Selective inhibitor shows early promise in patients with RET-altered cancers

16.04.2018 Health Problems

BLU-667, a next-generation inhibitor that selectively targets the oncogenic receptor tyrosine kinase RET, was well tolerated and had broad clinical benefit in patients with advanced cancer that had progressed on previous therapies including multikinase inhibitor therapy. Proof-of-concept data will be presented from an ongoing phase I clinical trial at the AACR Annual Meeting 2018, April 14-18, in Chicago. “RET-altered cancers […]